you, including will targets. comments and profit our to our adjusted thank our updated I'll fourth today our quarter full state Brian. results of fiscal operating Today, outlook, long-term overview XXXX I XXXX and an otherwise. fiscal then adjusted refer fiscal Well, results, year provide XXXX I'll discuss growth My unless segment
provided call. strong fourth were results quarter to delivered prior in earnings share with we our We XX% diluted guidance the third increase compared per quarter These of was the year. $X.XX, right results. line on Earnings an
leading the strength a each results core breadth as businesses. of company growth in Our strong of with healthcare services performance operating demonstrate in our diversified McKesson's
a year lower share by $XX.XX, growth as full X% Pharmaceutical US McKesson's the by segment, of result in divestitures year-over-year, earnings increased in segment offset contributions European For diluted the International driven completed of lower share a partially count the per the businesses. in
receivable our earnings items, $X.XX diluted related included to vaccine found tests the the the $X.XX following of Full storage government, to related the the government of distribution distribution tax be $X.XX also Ventures' in TRA or related $X.XX $X.XX to losses supplies to kitting, early presentation. McKesson associated year on also with earnings investments. termination Healthcare, and share ancillary XX, program, Change net with to the COVID-XX COVID-XX per can certain agreement and and for centralized equity related appendix slide US US the which to related
communicated Excluding share per target. diluted year-over-year, items, increased rate long-term growth certain earnings these previously XX% above our
results Our value. year strong growth commitment sustainable our are broad-based ongoing and and shareholder to reflect full long-term deliver
financial turn We to long-term on that impacted fourth I deliver GAAP-only highlight I growth item value results, and want company to Before differentiated results. strategically the managing quarter customer one our well profitability. to consolidated focused as as remain our
or innovation value, certain sustainable headcount include delivering drive facilities. initiatives of we during broad XXXX, infrastructure, fourth optimization. fiscal set These of of operational initiatives simplify support a growth, downsizing and and cost our increased reductions to quarter and announced the exit of In the efficiencies
$XXX as to Pharmaceutical of real anticipate estate million by substantially corporate end and and During completed and Technology the Solutions of segment, these asset million includes well recorded be certain within XXXX. and fourth segment, our of charges other quarter, pharmaceutical segment, within fiscal accelerated corporate. Technology US our within employee-related including within we impairments, total We as which charges Solutions US our approximately primarily asset the impairment related depreciation, severance to costs $XX charges initiatives, Prescription Prescription
to our now Moving consolidated results.
Fourth increased quarter revenues quarter, year growth European fourth the volumes consolidated customers, Our results divestitures national to full increased in $XX.X for a including businesses. the $XXX.X result increased revenues product year partially billion. were McKesson's billion X% of driven X% Pharmaceutical retail the the and segment, in full to in offset as the from lower US account by International segment completed of specialty by
XXXX. the impact full quarter, quarter X%. the billion Gross including European Excluding to profit operations, in for revenues the in divestitures, these decrease year of increased compared business was completed fiscal the XX% when the and XX% a of fourth $X.X
a year, decrease profit was the billion, $XX.X of X%. gross For full
gross X% European primarily in and the result X% business as and Technology in of and fourth profit divestitures, operations a completed US year, quarter Pharmaceutical the Excluding Solutions growth impact segments. the our full Prescription in increased of
largely expenses our decreased full the and year, in litigation completed lower International segment driven XX% and in Operating by for the European quarter divestitures opioid XX% costs.
of the year. divestitures, both operating X% fourth Excluding completed our increased the business quarter the in operations full impact the and European and expenses
quarter Fourth $X.X increased from completed divestitures Solutions and the including from segment, growth the Technology operating by profit contributions the to growth in offsetting in Prescription than Pharmaceutical driven more International X% impact program billion, our solid generics segment. US
by completed and contributions offset $X by items to Full American billion, increased primarily our year operating segment International in growth year-over-year. North our from partially in COVID-XX related divestitures lower led businesses, profit these X%
When pre-tax benefit Healthcare in the products, TRA X% and increased full COVID-XX $XXX third year fourth related the in the equity with termination McKesson related losses X% the the distribution XXXX. impact when the million gains Ventures' fiscal early a investments, compared and to or to quarter the related for profit associated with operating quarter of to excluding of of Change net
primarily tax interest expense XX.X% line higher the below for rate year, the original increase full line, the guidance. quarter for our The the the Moving and due was quarter million interest in in and was for $XX was Effective year. with rates. from impacts full XX.X% to million $XXX
rate decrease driven year-over-year. results, quarter by timing average outstanding was quarter-to-quarter, and can the discrete fourth up mix Wrapping tax reminder, items. of vary weighted a our tax our income effective a of our As X% of consolidated $XXX shares million, diluted
US to and seven Turning slides full through with results, quarter Pharmaceutical. and fourth year starting XX found which segment be on our can
momentum efficient capabilities, and Our we're with business business services pleased of is growing scaled in a depth breadth and US segment. our the the Pharmaceutical and comprises including this and platform, oncology
increased quarter increase across were $XX.X branded which an from including national of growth of by products, account all XX% and market conversions. specialty volume was Fourth to customers driven growth billion, partially revenues by offset segments, volumes generic year-over-year, higher retail customer
and and We program. Fourth with sourcing providers our program, in for operating year by quarter increased XX% of contributions profit driven distribution led market products by from fundamentals strength X% to million performance and full to stable health generics operations. growth specialty the billion, $X.X the $XXX the systems increased to and pleased increased our generics the of our remain of
and and continue to We customers delivering low supply. value to provide cost stable our solid partners
government quarter contract the quarter, operating of the compared million share $X.XX profit distribution Our per per an or million with prior approximately $X.XX $XX the in fourth in or share $XX US benefit for fourth of vaccine provided the year. COVID-XX to
For $XXX provided the or contract a of in benefit million fiscal full year, XXXX. to this compared $XXX per million a $X.XX per share share or $X.XX
segment target. Solutions Technology results, $X.X operating compared Pharmaceutical billion, in the by X% growth transaction of were third-party X% and prescription in fiscal growth for ahead year in which our an segment's fourth increase quarter business vaccine the fourth quarter adherence access the When year-over-year, the long-term and and logistics of US solutions XX% to In segment, Prescription revenues volumes volumes. profit delivered distribution, excluding the full XXXX COVID-XX of of were impact growth driven
support to customer Fourth we were increased XX% growth year the the positively of million, well growth, results due success increased profit and brands annual increased operating partially activities affordability as commercial by verification quarter million, access Fourth operating $XXX also serve. as impacted to full profit and to quarter XX% $XXX by in driven volume solutions.
strong services, over the their of McKesson and patients and number medicine solutions results line history. was suite quarter, XX to the times in Through access in million patients our helps performance produced in the a year guidance. quarter This segment's highest fourth comprehensive of assisted fourth original with full segment
revenues were $XXX profit In Solutions. year-over-year of fourth the was of billion, to decrease decrease Medical XX%. million, operating a a and Surgical now quarter, Moving X% $X.X
X% For the to profit full year, operating declined billion. $X.X
of and year program, and illness in activities offset compared storage government's the to contribution primary season by tests impacted and growth year. ancillary sourcing US quarter from Fourth supplies, partially lower COVID-XX sales the results of distribution lower care including in business, the COVID-XX were prior full favorable kitting, testing by
to tests XXXX. with share and compared kitting, fourth quarter from contract of fourth in $X.XX our quarter of ancillary a or fiscal $XX COVID-XX Contribution in million, total for million US the the or of the government and per $X.XX distribution the per share supplies storage provided benefit $XX
share operating million, year upper related million full provided. and impact XXXX. X% segment or $XXX to the items, full fiscal or was of original of share When the profit items fourth to a fiscal compared provided end in XXXX for we per guidance per $X.XX year the COVID-XX the benefit XX% results, quarter the compared $XXX the delivered $X.XX excluding growth For which of that range in related the at of COVID-XX
let fourth $XX results. a and quarter of adjusted was On of FX basis, XX%. was me International year-over-year decrease an million, million, profit billion, were profit XX%, and billion, XX% fourth revenues address operating in operating $X.X $XX decrease of a decrease a Next, decrease of our were Revenues the quarter a $X.X XX%.
XX%. For European year, our divestitures and on the year Fourth in profit quarter full year-over-year an effects reflect within operating completed basis the results by businesses. full FX-adjusted decreased the
decrease expenses in of were a $XXX In year-over-year. up the XX% million wrapping review, our segment quarter, corporate
Change Healthcare prior which of $XXX year. a year of expenses positively Corporate pre-tax opioid-related TRA expenses the of in agreement tax For quarter. early with termination the were and $XXX lower the to by third full compared the corporate fourth expenses benefit the were to quarter impacted full-year, the related in decrease a million included million, or XX%, receivable
losses During $X.XX to $X or $XX fourth quarter, we or the million McKesson $X.XX compared per net XXXX. quarter had of to losses share within in investments Ventures' related the approximately net million, the share equity of of portfolio fiscal per
full to compares approximately XXXX. for $XX portfolio full of per net within $XX equity For approximately Ventures' year share McKesson related losses per net the or $X.XX million, of or investments had This our to gains McKesson fiscal year, the $X.XX million, share.
the portfolio and performance results quarter-to-quarter. with As on growth-stage the by influenced this several individual through digital McKesson pleased obtained financials holds and the Ventures' equity health consolidated of reminder, and each investments we've be a can insights The services portfolio. companies, impacts in we're investment
And as a or gains losses, magnitude can investments in McKesson's of which result, for each timing result may the vary and investment.
Excluding the the within full benefit decreased XX% the the and from expenses and gains corporate the TRA, fourth McKesson respectively. net losses termination, quarter Ventures' early and and XX% portfolio, or in year
Turning on be slide now deployment, our capital can XX. position cash to which found and
on For cash strength the and year, flow, of capital capital working fiscal we generated the reflecting businesses, efficiency our focus broad-based disciplined the investment. record
For free capital our $X.X our investments the generated of including strategic pillars in to include as cash oncology $XXX services in billion full expenditures, and distribution support year, well as centers. we flow, of which biopharma million investments
balance strong shareholders quarter. to the sheet share fourth our return in $XXX used We repurchases, $X.X million including billion to through
new fiscal allows our share quarter, few XXXX a the speak about program, During minutes. for billion $X of a we repurchase up repurchases. entered to guidance repurchase share in new I'll which
dividend we XXXX. returned line remain growth. for free shareholders committed When with to and combining cash of dividends flow we the full approximately paid paid, XX% $XXX year, growing earnings fiscal in with share Additionally, we of the in to repurchases dividends million
shareholders. total returned do amount, of beginning to We method returned value through we $XX.X through to capital approximately repurchases dividends. outstanding as approximately XX%. $XX.X has continue we billion share drive the of billion our Of been to repurchases, XXXX, see by a shares fiscal for share deployment and this cash shareholders Since our utilize
to Our our performance, capital combined to strong value. operating our shareholders, driving commitment of return reinforces shareholder
a few outlook for our fiscal Now, XXXX. me spend let minutes discussing
can on do than outlining provided are following a GAAP 'XX Rather I'll As instead so basis, through consolidated be a additional non-GAAP items with the basis. slide metrics walk full forward-looking of of each reminder, XX on in key guidance. the provide XX list details through supplemental guidance on slides we adjusted an fiscal assumption, our A our not found beginning presentation. assumptions you
strong growth that are Fiscal These the profit, that year delivering our our beginning a we discussed confidence per flow increased profit, will our cash have exceeded strong results earnings 'XX where expect we levels and of share and operating they year was we've generation. guidance continue at share that outlook. laid robust year. of full and cash-flow and Strategies May out operating to we today deliver earnings per last
investments supplemented share to diluted when which XX% to XX% when 'XX, We benefit our core related per associated $XX.XX net share related items, of across Change Healthcare $XX.XX items, in in operating of termination fiscal Ventures' earnings fiscal anticipate TRA a $X.XX $X.XX increase anticipate to for businesses contemplates earnings early operating with related We excluding profit disciplined of related diluted McKesson COVID-XX capital excluding $X.XX 'XX and with growth the fiscal COVID-XX per to the equity each by of losses to XXXX. deployment.
start distribution by the me as of US the COVID-XX McKesson COVID-XX of to items and government's for well 'XX our customers. has support onset our storage central ancillary pandemic, and played of distribution of providing vaccines tests in the approach in distribution outlook. providing our COVID-XX the discussing role a as Let kitting, fiscal supplies related the Since to
anticipate the the fiscal impact in Looking we ahead of be items, COVID-XX results. tests US of XXXX including completion scheduled will fiscal to that July to XXXX, 'XX related from our COVID-XX and government contracts COVID-XX with immaterial
these guidance such, provide to per diluted items specific metrics will share longer going forward. As we no earnings
Let for the me segments. discuss outlook our
Pharmaceutical segment. retail, across US across platform of value provider to core continue in we're pleased The customer the we resonates anticipate several with systems channels. health our growth seeing and growth and We distribution be proposition the settings
to increase also care outcomes. of practice has platform. largest communities advanced Network, Oncology and expand further local better its anticipate footprint oncology in patient oncology the growth into the continued We to US management organization availability US the in
providers grow with to X,XXX network. provider the in the footprint over continue We
Research formed offerings biopharma our advances lifecycle. further Institute the Cannon venture pharmaceutical This at fiscal Sarah with entire and a XXXX. in the We partnership proposition across companies joint enhances our differentiated
Additionally, price 'XX in do to We fiscal increases in increases 'XX. we pharmaceutical anticipate line saw in in with we that fiscal not 'XX, the repeat anticipate experienced be fiscal increases fiscal XXXX. branded to price in higher
X% XX%, our fundamentals generics segment, value business, of with be anticipate increase yet to the the When approximately Pharmaceutical provide programs we up excluding competitive, our X% fiscal to to strong remain Within stable, and impact sourcing profit to fiscal operating our operating to customers. for 'XX, XXXX, flat we to revenue X%. Wrapping for to continue X% anticipate the distribution profit growth from vaccine year-over-year. increase COVID-XX US
anticipate In our reflecting XX%, Prescription Solutions and segment, to XX%, growth and profit and access and affordability services. to continued X% growth growth solutions transaction higher organic we of the Technology operating across revenue volumes of XX%
average the Within less services our previous full of the the XX% slightly revenues, three profit Prescription years. than Technology represent XPL than Solutions full while of represented year year on half segment, more over typically services operating fiscal
the I've in of previously, stated this revenue vary quarter-to-quarter. can segment mix
its a full acquired and advanced fiscal utilizing by Rx 'XX full employers we mix with Solutions, we reduce health costs 'XX, which prior be product balance drug year over However, anticipate analytics the capabilities. years. In Savings year, in to prescription consistent also plans fiscal helps of
leverage profile with value opportunities revenue the we'll patient over that are This suite margin capabilities. segment the from with last ongoing workflows. provider and The and during realize perform of integration synergies. grow and acquisition's We're investments well, to adherence that to to automated strategic and reflects access, pleased affordability into solutions strong our years continues our scale integrated solutions continue our progress as products fiscal its higher expand we the this and provide growth technology and 'XX, and begin next-generation to
its X% segment, anticipate depth alternate growth and breadth be Medical site well and solutions. reported and in the In the The XX%. lab market, to the profit positioned leverage Medical throughout including approximately X% of to business Surgical X% a the care revenues operating decline to to remains Surgical to Solutions services we business primary growth decrease
US for Our supplies kitting, government of July contract storage XXXX. the in distribution ancillary ends and of with the
to to results. 'XX be expect results. a volumes anticipate 'XX we We contract from a lower of anticipate decline continue and compared to contribution we to this the 'XX modest fiscal immaterial level and COVID-XX immaterial to tests, fiscal remaining be And at to impact fiscal while
impact of 'XX XX% XX% year-over-year. COVID-XX these operating we items results, to anticipate the to profit related fiscal from Excluding increase
Finally, closed in XX% and revenues loss and transactions International to profit segment, the XX% businesses profit we to the fiscal and we year-over-year anticipate by by to of This contribution from decline during includes operating XX%. operating that 'XX. close decline to-date to expect decrease XX% we've to
offset divestitures. explore in third to alternatives from exit our continue to resulting and repurchases any the We call, I strategic on as remaining operations we quarter to mentioned deploy earnings European dilution our Norway intend to capital through share
turning capital deployment. flow and to cash Now
businesses our remain allocation priorities and cash generate free American unchanged. North continued Our to flow capital strong
We deployment to growth continue efficient be profitable of and on capital. focused
value on Our our illustrates shareholder XX% capital return creation. focus invested on
to priorities Our pursue concurrently. strong balance multiple sheet provides us flexibility capital the allocation
are We increasingly acquisitions on-strategy and organic that to growth will through prioritize multiples. through opportunities, however, appropriate continue
to software capitalized net we expenses. For billion, approximately flow free acquisitions and $X.X billion of fiscal property cash anticipate $X.X 'XX, of
shareholders. also We committed to to remain returning capital our
Our 'XX. plans outlook fiscal billion incorporates shares repurchase to approximately $X.X of in
to As weighted average share the a fiscal 'XX $XXX in shares of be to diluted $XXX range outstanding activity, the million. million repurchase we for result approximately of estimate
Combining $XX.XX $XX.XX. all of earnings these share adjusted to to elements per leads
our long-term Norway, the above previously framework. share XX% demonstrates approximately earnings shareholder anticipate the XX% target we operations provided. contribution remaining in our diluted in rate European further items Excluding The per and COVID-XX-related which to the outlook impact from of growth is we strong value of creation fiscal 'XX,
to and of deployment efficient continue growth be profitable We focused capital. on
now adjusted found on segment can XX. to growth which Turning be targets, long-term slide profit operating our
and scheduled and end differentiated government we XXXX, in our building strategic of As COVID-XX run executing to are the capabilities. assets as initiatives to in with off from against contribution related our Europe continues US the on to contracts July guided, remain committed
a demonstration targets, to our of result, strategies, leading position. and we be our market raising growth As are financial the strong long-term a execution of pleased positions our
X%, For Medical to growth, US which and XX% from the from XX%. up XX%, anticipate X% growth, long-term we Solutions is X% Pharmaceutical, Solutions XX% up Technology from to up Surgical long-term XX% to long-term growth, Prescription XX%
strong aligned and many sustainable moving continue for our alike. I our shareholders opportunities we'll remain members customers, the to value long-term forward, on confident provide to team With growth our momentum focus deliver underlying and superior growth
provide. we a that the in can scale market with conclusion, and strength In McKesson well-positioned only are unique
reach We and will expand in of biopharma continue ecosystem to oncology our invest services as the our we platform. strategies
XXXX demonstrated, are our producing strategies working, all fiscal value for As stakeholders.
financial have a tremendous financial and sustainable and across creation. growth, and outlook, value the our execution to cash profit deliver flows momentum position us framework business, strong We shareholder
We our have strategy. in products services and and and confidence our our teams great in
let turn the me now your operator for back questions. that over to it With
